Auxly Cannabis: Analyzing the Stock Performance

Daniel Collins - finance.yahoo.com Posted 5 years ago
image
Auxly Cannabis: Analyzing the Stock Performance

Auxly Cannabis: An Overview for Investors## Stock performanceOn January 7, Auxly Cannabis’ (CBWTF) stock price closed at $0.67, which is ~2.95% growth from its close of $0.65 on January 4. Auxly Cannabis’ stock price has grown consistently since December 24. On December 24, Auxly Cannabis’ stock price grew ~15.74% to $0.54 from $0.46 on December 21. On December 24, the company hit its 52-week low of $0.44.Auxly Cannabis’ stock price closed at $0.67 on January 7, which is ~52% growth from its 52-week low of $0.44 on December 24. The stock hit its 52-week high of $2.7 on January 17, 2018.## Financials in a nutshellAuxly Cannabis reported revenues of 512,000 Canadian dollars in the third quarter. The company reported net expenses of 17.1 million Canadian dollars in the third quarter—compared to 5.2 million Canadian dollars in the third quarter of 2017.Vivo Cannabis (VVCIF) generated revenues of 4.3 million Canadian dollars in the third quarter. HEXO (HYYDF) reported revenues of $5.7 million in the first quarter of fiscal 2019.Auxly Cannabis’ net comprehensive loss in the third quarter was 4.6 million Canadian dollars—compared to 5.7 million Canadian dollars in the same period the previous year.In the first nine months of 2018, Auxly Cannabis’ net revenues were 512.00 Canadian dollars. During the same period, Auxly Cannabis reported unrealized gains and fair value changes of 7.1 million Canadian dollars. The company reported net expenses of 36.8 million Canadian dollars during the first nine months of 2018—compared to 8.3 million Canadian dollars during the same period the previous year.## Analysts’ recommendationsAmong the two analysts tracking Auxly Cannabis in January 2019, one recommended a “strong buy,” while one recommended a “buy.”Continue to Next PartBrowse this series on Market Realist: * Part 2 - Auxly Cannabis: Business Strategies and Financial Projections * Part 3 - Auxly Cannabis: Developments and Cash Equivalents

Story continues